YaoGeJu

Public drug landscapesDrug landscape

Vancomycin Hydrochloride for Injection

As of 13 November 2026, for Vancomycin Hydrochloride for Injection, 4 applications are listed as under review at China's CDE; 4 companies have filed new generic applications in 2026; the chemical-drug catalogue lists 12 holders.

Companies, stages and changes, with each record available on this page.

Last 90 days: No longer listed under review: 1 application

Current coverage may be incomplete

Follow for free
Complete CDE snapshot
2026/11/13 06:42
Matching scope
Same generic name; dosage forms and combinations kept separate

US Orange Book listing

The brand names come from the US FDA Orange Book and describe US listing records for this active ingredient. They do not indicate that products under these brand names are approved or sold in China, or that Chinese applicants are affiliated with US holders.

Orange Book source export date: 2026/11/06. Version: 2026-11-06.

Showing 4 of 4 distinct brand names.

A brand with different source forms or statuses can appear on multiple rows and in both groups. Distinct brand names are counted once globally, with a limit of five.

Verified official English dosage form: for Injection. Listings are grouped by the source dosage form and route; records without a clear correspondence are listed in the other group. Grouping does not establish product equivalence.

Same dosage form

No listings in this group among the displayed brand names.

Other dosage forms of the same ingredient

Brand nameApplicant (source text)Application numberDosage form (source text)Route (source text)Marketing status (source text)Approval date
VANCOCIN HYDROCHLORIDE ANI PHARMACEUTICALS INC NDA 050606 · Product no. 001, 002 CAPSULE ORAL HUMAN PRESCRIPTION DRUG 1986/04/15
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER BAXTER HEALTHCARE CORP NDA 050671 · Product no. 001 SOLUTION INTRAVENOUS HUMAN PRESCRIPTION DRUG 1993/04/29
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER BAXTER HEALTHCARE CORP NDA 050671 · Product no. 003 SOLUTION INTRAVENOUS HUMAN PRESCRIPTION DRUG 1999/03/01
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER BAXTER HEALTHCARE CORP NDA 050671 · Product no. 002 SOLUTION INTRAVENOUS HUMAN PRESCRIPTION DRUG 2010/12/20
FIRVANQ KIT AZURITY PHARMACEUTICALS INC NDA 208910 · Product no. 001, 002 FOR SOLUTION ORAL HUMAN PRESCRIPTION DRUG 2018/01/26
TYZAVAN HIKMA PHARMACEUTICALS USA INC NDA 211962 · Product no. 001, 002, 003, 004 SOLUTION INTRAVENOUS HUMAN PRESCRIPTION DRUG 2019/02/15
TYZAVAN HIKMA PHARMACEUTICALS USA INC NDA 211962 · Product no. 005, 006, 007 SOLUTION INTRAVENOUS HUMAN PRESCRIPTION DRUG 2020/05/13
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER BAXTER HEALTHCARE CORP NDA 050671 · Product no. 004, 005 SOLUTION INTRAVENOUS HUMAN PRESCRIPTION DRUG 2024/01/25

Same-form/route listings come first, followed by other forms/routes. Within each group, source prescription/OTC listings precede discontinued listings; unknown statuses are last. Each status bucket is ordered by earliest approval date, ascending: pre-1982 records first, missing dates last; ties by brand name, application number and product number. The first five distinct brands in this order are selected globally. All retained source facts for those brands are shown in their own groups; a brand spanning both groups counts once.

Ingredient cross-list details ↗

Which companies are listed, and at what stages?

Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.

Chemical-drug catalogue

Loaded records: 12 holders; 3 in the quality-and-efficacy consistency-evaluation category, and 8 in the new chemical-registration-classification generic category. Category counts may overlap.

Marketing authorization holderManufacturerApproval numberApprovedStrength / specificationCatalogue category (source text)View source
Fu An Pharma Group Hubei Ren Min Pharmaceutical Co., Ltd. romanizedFu An Pharma Group Hubei Ren Min Pharmaceutical Co., Ltd. romanized国药准字H202650432026/06/30See sourceGeneric approved under the new chemical-drug registration classificationCDE
Anhui Pioneer Pharmaceutical Co., LtdAnhui Pioneer Pharmaceutical Co., Ltd国药准字H202642322026/05/07See sourceGeneric approved under the new chemical-drug registration classificationCDE
NORTH CHINA PHARMACEUTICAL COMPANY.LTDNORTH CHINA PHARMACEUTICAL COMPANY.LTD国药准字H202552302025/08/26See sourceGeneric approved under the new chemical-drug registration classificationCDE
Hainan Brilliant Pharmaceutical Co., Ltd.Hainan Brilliant Pharmaceutical Co., Ltd.国药准字H202537812025/04/01See sourceGeneric approved under the new chemical-drug registration classificationCDE
Shandong Lukang Pharmaceutical Co.,Ltd.Chengdu Tong De Pharma Co., Ltd. romanized国药准字H202449552024/09/19See sourceGeneric approved under the new chemical-drug registration classificationCDE
Nanjing Heng Dao Pharmaceuticals Technology Co., Ltd. romanizedJiangsu Jiu Xu Pharma Co., Ltd. romanized国药准字H202448082024/09/03See sourceGeneric approved under the new chemical-drug registration classificationCDE
Hainan Pu Li Pharmaceutical Co., Ltd. romanizedHainan Pu Li Pharmaceutical Co., Ltd. romanized国药准字H202436602024/05/08See sourceGeneric approved under the new chemical-drug registration classificationCDE
Li Zhu Group Li Zhu Pharmaceutical Factory romanizedLi Zhu Group Li Zhu Pharmaceutical Factory romanized国药准字H201933782023/04/05See sourceDrug that passed quality-and-efficacy consistency evaluationCDE
Zhejiang Hai Zheng Pharma Co., Ltd. romanizedZhejiang Hai Zheng Pharma Co., Ltd. romanized国药准字H200842682021/11/15See sourceDrug that passed quality-and-efficacy consistency evaluationCDE
Zhejiang Pharmaceuticals Co., Ltd. romanizedZhejiang Pharmaceuticals Co., Ltd. Xin Chang Pharmaceutical Factory romanized国药准字H200333662021/06/03See sourceDrug that passed quality-and-efficacy consistency evaluationCDE
VANCOCIN ITALIA S.R.L.VIANEX S.A.(PLANT C)H201401741988/10/15500mgImported originator drugCDE
YaoPharma Co., Ltd.YaoPharma Co., Ltd.国药准字H202549042025/07/22See sourceGeneric approved under the new chemical-drug registration classificationCDE

Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.

NHSA drug codes

Loaded records: 15 distinct approval numbers and 14 companies.

Company / applicantApproval numberStrength / specificationNHSA classNHSA drug codeView source
Li Zhu Group Li Zhu Pharmaceutical Factory romanized国药准字H20193378See sourceCategory BXJ01XAW001B001010100453NHSA
YaoPharma Co., Ltd.国药准字H20254904See sourceCategory BXJ01XAW001B001010101066NHSA
NORTH CHINA PHARMACEUTICAL COMPANY.LTD国药准字H20255230See sourceCategory BXJ01XAW001B001010102690NHSA
Anhui Pioneer Pharmaceutical Co., Ltd国药准字H20264232See sourceCategory BXJ01XAW001B001010104339NHSA
Zhejiang Hai Zheng Pharma Co., Ltd. romanized国药准字H20084268See sourceCategory BXJ01XAW001B001010104641NHSA
Zhejiang Pharmaceuticals Co., Ltd. Xin Chang Pharmaceutical Factory romanized国药准字H20033366See sourceCategory BXJ01XAW001B001010104747NHSA
Hainan Brilliant Pharmaceutical Co., Ltd.国药准字H20253781See sourceCategory BXJ01XAW001B001010105791NHSA
Hainan Pu Li Pharmaceutical Co., Ltd. romanized国药准字H20243660See sourceCategory BXJ01XAW001B001010105801NHSA
Fu An Pharma Group Hubei Ren Min Pharmaceutical Co., Ltd. romanized国药准字H20265043See sourceCategory BXJ01XAW001B001010109554NHSA
VANCOCIN ITALIA S.R.L.国药准字HJ20140174See sourceCategory BXJ01XAW001B001010178400NHSA
CJ HealthCare CorporationH20171132See sourceCategory BXJ01XAW001B001010179134NHSA
Gentle pharma Co.,Ltd.HC20150054See sourceCategory BXJ01XAW001B001010179360NHSA
Nanjing Heng Dao Pharmaceuticals Technology Co., Ltd. romanized国药准字H20244808See sourceCategory BXJ01XAW001B001010183035NHSA
Shandong Lukang Pharmaceutical Co.,Ltd.国药准字H20244955See sourceCategory BXJ01XAW001B001010183198NHSA
Li Zhu Group Li Zhu Pharmaceutical Factory romanized国药准字H20193378See sourceCategory BXJ01XAW001B001010200453NHSA
Anhui Pioneer Pharmaceutical Co., Ltd国药准字H20264232See sourceCategory BXJ01XAW001B001010204339NHSA
Zhejiang Hai Zheng Pharma Co., Ltd. romanized国药准字H20084268See sourceCategory BXJ01XAW001B001010204641NHSA
Hainan Brilliant Pharmaceutical Co., Ltd.国药准字H20253781See sourceCategory BXJ01XAW001B001010205791NHSA
Hainan Pu Li Pharmaceutical Co., Ltd. romanized国药准字H20243660See sourceCategory BXJ01XAW001B001010205801NHSA
Fu An Pharma Group Hubei Ren Min Pharmaceutical Co., Ltd. romanized国药准字H20265043See sourceCategory BXJ01XAW001B001010209554NHSA
Gentle pharma Co.,Ltd.HC20150054See sourceCategory BXJ01XAW001B001010279360NHSA
Nanjing Heng Dao Pharmaceuticals Technology Co., Ltd. romanized国药准字H20244808See sourceCategory BXJ01XAW001B001010283035NHSA
Nanjing Heng Dao Pharmaceuticals Technology Co., Ltd. romanized国药准字H20244808See sourceCategory BXJ01XAW001B001010383035NHSA
Zhejiang Hai Zheng Pharma Co., Ltd. romanized国药准字H20084269See sourceCategory BXJ01XAW001B001020104641NHSA
Zhejiang Hai Zheng Pharma Co., Ltd. romanized国药准字H20084269See sourceCategory BXJ01XAW001B001020204641NHSA

Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.

Current under-review applications

Loaded records: 4 filings and 4 distinct first applicants.

Generic 4

Current under-review applications
Company / applicantAcceptance numberApplication typeAcceptedStrength / specificationView source
Nanjing Hai Na Pharmaceutical Co., Ltd. romanizedCYHS2600957Generic2026/04/24Not stated by sourceCDE
Yi Teng Pharmaceuticals (Zhuhai) Co., Ltd. romanized; Nanjing Jian You Sheng Hua Pharmaceutical Co., Ltd. romanizedCYHS2600726Generic2026/03/26Not stated by sourceCDE
Shenzhen Li Jian Pharma Co., Ltd. romanizedCYHS2601766Generic2026/07/23Not stated by sourceCDE
Shijiazhuang No.4 Pharmaceutical Co., Ltd.CYHS2600636Generic2026/03/10Not stated by sourceCDE
New generic filings in 2026

Loaded records: 4 filings and 4 distinct first applicants.

New generic filings in 2026
Company / applicantAcceptance numberApplication typeAcceptedStrength / specificationView source
Nanjing Hai Na Pharmaceutical Co., Ltd. romanizedCYHS2600957Generic2026/04/24Not stated by sourceCDE
Yi Teng Pharmaceuticals (Zhuhai) Co., Ltd. romanized; Nanjing Jian You Sheng Hua Pharmaceutical Co., Ltd. romanizedCYHS2600726Generic2026/03/26Not stated by sourceCDE
Shenzhen Li Jian Pharma Co., Ltd. romanizedCYHS2601766Generic2026/07/23Not stated by sourceCDE
Shijiazhuang No.4 Pharmaceutical Co., Ltd.CYHS2600636Generic2026/03/10Not stated by sourceCDE
API registrations

Non-component matches: 6 companies with A status and 5 I-status records. Component matches are listed separately and excluded from these counts.

NameCompany / applicantRegistration numberStatusName matchSource update dateView source
万古霉素 · No verified English nameYa Sai Li (Tai Zhou) Pharmaceutical Co., Ltd. romanizedY20260000210ISalt-normalized ingredient2026/04/20CDE
盐酸万古霉素 · No verified English nameZhejiang Chang Hai Pharmaceutical Co., Ltd. romanizedY20240000397IExact ingredient2024/04/22CDE
盐酸万古霉素 · No verified English nameBei Da Pharmaceuticals Chongqing Da Xin Pharma Co., Ltd. romanizedY20230000840IExact ingredient2023/10/19CDE
盐酸万古霉素 · No verified English nameZhejiang Chang Hai Pharmaceutical Co., Ltd. romanizedY20230000281AExact ingredient2025/03/06CDE
盐酸万古霉素 · No verified English nameBei Da Pharmaceuticals Chongqing Da Xin Pharma Co., Ltd. romanizedY20210000777IExact ingredient2024/11/12CDE
盐酸万古霉素 · No verified English nameHe Xin Pharmaceuticals (Shandong) Co., Ltd. romanizedY20190000434IExact ingredient2020/06/03CDE
盐酸万古霉素 · No verified English nameZhejiang Pharmaceuticals Co., Ltd. Xin Chang Pharmaceutical Factory romanizedY20190009487AExact ingredient—CDE
盐酸万古霉素 · No verified English nameHua Bei Pharmaceutical Hua Sheng Co., Ltd. romanizedY20190006976AExact ingredient—CDE
盐酸万古霉素 · No verified English nameZhejiang Hai Zheng Pharma Co., Ltd. romanizedY20190006263AExact ingredient2025/07/04CDE
盐酸万古霉素 · No verified English nameZhejiang Pharmaceuticals Co., Ltd. Xin Chang Pharmaceutical Factory romanizedY20180001287AExact ingredient2025/03/18CDE
盐酸万古霉素 · No verified English nameLi Zhu Group Fuzhou Fu Xing Pharmaceuticals Co., Ltd. romanizedY20170000276AExact ingredient2026/09/03CDE
盐酸万古霉素 · No verified English nameYa Sai Li (Tai Zhou) Pharmaceutical Co., Ltd. romanizedY20170000173AExact ingredient2024/10/22CDE

A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.

What changed recently?

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.

Trial registration does not mean an application will follow.

This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.

NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/13 06:39. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.

This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.

  1. 2026/11/06No longer listed under review

    Hubei Mei Lin Pharma Co., Ltd. romanized

    CYHS2501535

    Fact date: 2026/11/06 · Site observation date: 2026/11/06

    Accepted: 2025/04/23

    not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked

    View source ↗

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/13 06:42
Chemical-drug catalogue
Last successful update: 2026/11/13 06:39

Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.

Full API register
Last successful update: 2026/11/13 06:41
NHSA drug codes
Last successful update: 2026/11/05 06:45

The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.

NMPA drug delivery notices
Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete

First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.

Drug Clinical Trial Registry and Information Disclosure Platform
Last successful update: 2026/11/13 08:09 · Current coverage may be incomplete

Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.

This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.

Public-product searches scanned: 7/30; discovered pending details: 13. Record counts in unscanned portions remain unknown.

Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.

Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

Free follow

Follow changes to Vancomycin Hydrochloride for Injection

Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.

Confirmation links expire in 7 days. No digest is sent before confirmation; existing follows are not duplicated.

Sign in to choose products